Effect of empagliflozin on the renin-angiotensin system in patients with chronic kidney disease with and without type 2 diabetes - EMPagliflozin and RAs in kidney disease

Medical University of Vienna, Internal Medicine III, Clinical Div. of Nephrology and Dialysis0 个研究点目标入组 48 人开始时间: 2016年10月11日最近更新: 2019年12月10日

试验速览

暂无简介。

•CKD patients with type 2 diabetes
•Estimated GFR (calculated with the MDRD formula) between 15 and 59 ml/min (with CKD stage IIIa/b to IV)
•Albumin excretion rates of >30 mg/24 hours (UACR >30 mg/g)
•Fasting plasma glucose levels >126 mg/dl [7mmol/L] or HbA1c levels >6.5% (Definition of type 2 diabetes according to the diagnostic criteria set forth by the American Diabetes Association in 2009)
•CKD patients without diabetes
•Estimated GFR (calculated with the MDRD formula) between 15 and 59 ml/min (with CKD stage IIIa/b to IV)
•Albumin excretion rates of >30 mg/24 hours (UACR >30 mg/g)
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 18
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 30

•CKD patients with type 2 diabetes
•Age <18 years
•Severely impaired renal function (eGFR <15ml/min)
•Hyperkalemia above 5,1mmol/L
•Hypotension (systolic blood pressure lower than 120 mmHg on ambulatory measurement)
•Pregnant patients
•Patients planning pregnancy
•Body mass index < 18.5 kg/m2
•Total urinary protein excretion = 3.5 g/d
•CKD patients without diabetes
•Age <18 years
•Diabetic kidney disease
•Severely impaired renal function (eGFR <15ml/min)
•Hyperkalemia above 5.1mmol/L
•Hypotension (systolic blood pressure lower than 120 mmHg on ambulatory measurement)
•Pregnant patients
•Patients planning pregnancy
•Body mass index < 18.5 kg/m2
•Total urinary protein excretion = 3.5 g/d

发起方

Medical University of Vienna, Internal Medicine III, Clinical Div. of Nephrology and Dialysis